Board summary
Key figures
66,368
Registered population
60.2% aged 18–64
20.5%
Aged 65+
ICB 19.0% · England 17.9%
4.5%
Ethnic minority (non-White)
1.7% Asian · England 9.6%
48.1%
In IMD quintile 1
ICB 31.9% · England 21.0%
~31,329
Core20 residents (est.)
Resident basis; registered basis ~32,419 · see page 3
11,760
Hypertension register
+7.01% in 3 yrs · England +5.60%
815
SMI register
20.4% of Wirral (LAD)'s
1,871
COPD register
Reviews +6.73% in 3 yrs
Forecast to 2030
13,612
Hypertension patients, 2030
+1,852 on today
80.1%
QRISK ≥20% on statins, 2030
+5.69pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma and COPD annual reviews trail England.
Asthma reviews cover 61.3% of 5,360 patients (England 65.7%; 2,073 unreviewed) and COPD 70.0% (England 76.4%), which may reflect unverified recall barriers.
Primary CVD control leads while diabetes statins lag.
Hypertension BP monitoring reaches 91.3% (target treatment 70.2%) and QRISK ≥ 20% lipid therapy 67.0%, though diabetes-with-CVD statins are 83.2% (-0.01% 3-year change).
Population, age and ethnicity
Older patients comprise 20.5% of registrations alongside 26 catchment care homes
Wallasey PCN registers 66,368 patients, with 26 catchment care homes (744 beds; resident registrations unconfirmed). Patients aged 65 and over make up 20.5% of the list (13,621 patients), close to Wirral (LAD) (20.7%) but above NHS Cheshire and Merseyside Integrated Care Board (19.0%) and England (17.9%). Working-age adults represent 60.2% (39,961) and children aged 0-17 comprise 19.3% (12,786). Projected list growth to 2030 is 0.8% (Wirral (LAD) 1.2%, ICB 2.3%, England 2.3%; unverified methodology). Census data shows 95.5% White residents (Wirral (LAD) 95.2%, England 81.1%), leaving a 4.5% ethnic minority share; Census residents differ from registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wirral LA) | 1,517 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wirral LA) | 753 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wirral LA) | 25.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Wallasey PCN has 48.1% Core20 deprivation with a 96.7 pp spread across practices
In Wallasey PCN, 48.1% of registered patients live in Core20 areas, above Wirral (34.8%), the ICB (31.9%) and England (21.0%). Average IMD decile is 3.5 (England 5.5). Weighted practice share is 48.8%. Across captured practices, the range is 96.7 pp. Grove Rd Surgery records 3.4%, whereas Egremont Med Ctr and Leasowe Medical Practice each reach 100.0%. Somerville Med Ctr (7,092) and Central Park Medical Centre (6,437) hold the largest estimated Core20 volumes. Resident Core20 totals 31,329. Delivery should split intensive outreach at high-concentration practices from proactive volume recall.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
815
SMI register
1.22% recorded prevalence
484
Learning disability register
0.72% recorded prevalence
26
Care homes, 744 beds
In the PCN catchment
10.9%
Provide unpaid care
Wirral (LAD), Census 2021
Severe mental illness prevalence is 1.2% (815 patients; Wirral (LAD) 1.2%, ICB 1.1%, England 1.0%), representing 20.4% of Wirral's register. Learning disability prevalence is 0.7% (484 patients; Wirral (LAD) 0.8%, ICB 0.6%, England 0.6%). Crude recorded register prevalence does not establish unmet need or under-detection.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (England 1.0%). Recorded checks exceed England: blood pressure reaches 87.1% (England 83.4%), BMI 83.8% (England 82.1%), and smoking cessation offer 97.5% (England 94.2%), though smoking support fell 0.7 pp (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,760
Hypertension register
+7.01%
Register growth, 3 yrs
Wirral (LAD) +6.35% · England +5.60%
+4.56pp
BP control, under 80
≤140/90 · +4.05pp aged 80+
+1,852
More patients by 2030
Forecast 13,612 (20.12%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.6% (11,760 patients), exceeding England (15.2%) and NHS Cheshire and Merseyside Integrated Care Board (16.8%), while below Wirral (LAD) (18.0%). Blood pressure monitoring reaches 91.3% (England 90.0%; Wirral (LAD) 89.2%; ICB 88.3%), and treatment to target reaches 70.2% (Wirral (LAD) 67.9%; England 70.3%). However, secondary cardiovascular prevention lags: statin treatment in diabetes with CVD is 83.2%, trailing England (84.4%) and Wirral (LAD) (85.1%), with a 3-year change of -0.01% (England +1.0%). Statin treatment in diabetes with established CVD trails national and borough levels, indicating that the PCN should prioritise secondary-prevention recall for high-risk diabetic patients.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy reach 67.0%, above England (63.6%) and Wirral (LAD) (65.8%), alongside 74.0% in CKD (England 70.3%). Higher treatment rates than England across primary prevention groups indicate the PCN should sustain systematic cardiovascular risk assessment and lipid initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 145,777 | £2.40 | £1.71 | £1.86 | £349,865 |
| Cardiovascular (all), 2025 | 192,077 | £4.91 | £4.37 | £3.33 | £943,098 |
In 2026, lipid-modifying prescribing cost £2.40 per item across 145,777 items (spend £349,865), exceeding England (£1.86) and Wirral (LAD) (£2.00). This unit cost is £78,720 more than at England's unit cost across 145,777 items. Higher unit costs than England could reflect formulary choices, which a practice-level prescribing review would test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.06%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.09%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.5% (5,360 patients; England 6.6%) and COPD is 2.8% (1,871 patients; England 1.9%), alongside 2,867 asthma items prescribed per 1,000 aged 5-19 (England 1,488 rate). Yet annual reviews trail England for asthma at 61.3% (England 65.7%; Wirral (LAD) 63.2%; a modelled scale indicator of about 2,100 unreviewed patients) and COPD at 70.0% (England 76.4%). Lower review coverage alongside high prescribing could reflect recall barriers, which local practice audits would test.
Cancer register and children's immunisation
Cancer register prevalence is 4.4% (2,964 patients; England 3.8%). In childhood immunisations, age-5 MMR dose 1 reaches 97.9% (England 91.7%), but dose 2 drops 4.8 pp to 93.1%, sitting 1.9 pp below the 95.0% target. The 4-in-1 pre-school booster is also 93.1%, trailing the 95.0% target by 1.9 pp despite exceeding England (80.9%). Denominators are small (145 children).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), 19.5 pp below the 75.0% national ambition for 2028; staging completeness was 72.8% (13,490 of 18,522). Sizing this ICB gap indicates 2,635.5 (about 2,640) extra early-stage diagnoses were required in 2022, while early-stage share rose 2.6 pp from 2013 to 2022. At PCN level, cervical screening coverage is 69.4% (Wirral (LAD) 71.5%), with a 3-year change of -1.1% (Wirral (LAD) +1.2%). Screening rates below the borough may delay early cancer detection, making practice recall audits a priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For secondary cancer pathway standards, Wirral University Teaching Hospital NHS Foundation Trust achieved 77.647% against the 85.0% 62-day referral-to-treatment standard (7.4 pp below the standard) and 74.7058% on the 28-day faster diagnosis standard (0.3 pp below the 75.0% target), alongside 92.5266% on the 31-day combined standard (target 96.0%). Across NHS Cheshire and Merseyside Integrated Care Board, 62-day performance was 76.232% (8.8 pp below standard), 28-day faster diagnosis reached 77.2451% (2.2 pp above standard), and 31-day treatment was 95.7087% (0.3 pp below standard). These acute trust metrics describe system delays rather than PCN referral quality.
| Pathways within standard (%) | Wirral | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 73.26 | 77.96 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Liverpool | Mersey and West Lancashire | England |
|---|---|---|---|---|
| MRI | 1.54 | 6.42 | 14.04 | 21.40 |
| CT | 1.55 | 0.71 | 13.08 | 9.92 |
| Echocardiography | 5.07 | 12.55 | 34.88 | 28.48 |
| Colonoscopy | 32.81 | 33.14 | 18.04 | 30.83 |
| Gastroscopy | 17.73 | 44.99 | 18.17 | 29.02 |
| All 15 DM01 tests | 5.02 | 11.50 | 21.17 | 23.14 |
| Community services activity | Wirral residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 58,870 | 541,280 |
| Referrals | 13,315 | 97,150 |
| Patients with a contact | 17,205 | 146,240 |
Community services (residents of Wirral), Jun 2026 (provisional). In community health services activity, adults aged 65 and over accounted for 66.1% of all community contacts among Wirral borough residents (38,930 of 58,870 contacts, provisional June 2026 data). These figures capture borough-wide resident contacts rather than PCN-level delivery, reflecting high routine community care intensity for older adults across the local authority.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Grove Rd Surgery | 117 | 3.4 | 85.4% | 63.4% | 95.2% |
| Blackheath Med Ctr | 110 | 56.0 | 90.1% | 67.1% | 93.3% |
| Liscard | 95 | 78.4 | 64.3% | 56.8% | 91.8% |
| Somerville Med Ctr | 125 | 75.4 | 45.4% | 84.0% | 90.4% |
| Manor Health Ctr | 117 | 47.3 | 88.7% | 90.1% | 88.8% |
| Leasowe Medical | 102 | 100.0 | 75.9% | 63.7% | 87.4% |
| St Hilary | 119 | 6.7 | 66.2% | 64.8% | 85.5% |
| Village | 95 | 6.5 | 77.5% | 68.9% | 84.1% |
| Central Park | 114 | 72.7 | 52.8% | 71.7% | 79.6% |
| Egremont Med Ctr | 106 | 100.0 | 65.2% | 76.5% | 76.6% |
| St Georges | 123 | 19.8 | 41.6% | 68.0% | 66.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia (+0.9%) and learning disability (+0.5%) three-year register growth lagged England's rate
Three-year register growth in Wallasey PCN lagged England and Wirral (LAD) most for dementia (+0.9% vs +7.6% Wirral (LAD); England +6.0%) and learning disability (+0.5% vs +7.7%; England +5.4%). Heart failure review growth trailed England (+5.8% vs +8.7%), despite current review coverage of 85.4% exceeding Wirral (LAD) (77.0%) and England (78.5%). Three-year gains above England occurred in breast screening (+15.2% vs +8.4%), blood pressure control under 80 (+7.2% vs +3.2%), and COPD reviews (+6.7% vs +2.8%). Slower register growth could reflect under-detection or list turnover, but requires local clinical validation.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Learning disability register
Heart failure reviews
Asthma reviews
Diabetes HbA1c control
Breast screening (53-70)
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wirral (LAD) | Asset | PCN | Wirral (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (744 beds) | n/a | Schools (catchment) | 42 | n/a |
| Children's centres | 4 | 16 | Places of worship | 38 | 171 |
| Libraries | 3 | 18 | Primary schools (LA maintained) | 15 | 52 |
| Primary academies | 3 | 36 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma review coverage is 61.3% of 5,360 patients (England 65.7%; Wirral (LAD) 63.2%), leaving a scale indicator of 2,073 (about 2,100) unreviewed patients; COPD reviews are 70.0% (England 76.4%). For discussion: run structured asthma and COPD review and inhaler recall clinics, starting at high-volume and high-share Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Two-track Core20 and diabetes recall
Core20 share is 48.1% (England 21.0%; Wirral (LAD) 34.8%; 31,329 estimated residents; 96.7 pp spread). Diabetes statins with CVD (83.2% vs England 84.4%) and non-frail HbA1c <= 58 mmol/mol (57.1% vs Wirral (LAD) 58.1%) trail. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Dementia and learning disability register validation
Dementia is 0.8% (524 patients; Wirral (LAD) 1.0%; gap -5 to +122; 3-year growth +0.9% vs England +6.0%); learning disability is 0.7% (484 patients; gap -94 to +38; growth +0.5% vs England +5.4%). Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home primary care alignment (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustained SMI physical health monitoring (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Secondary prevention diabetic statin audit (p5) | Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Second dose MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Two-track Core20 and diabetes recall (p12) | Core20 cohort (IMD quintile 1) · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN & Practice |
| Option 3 · Dementia and learning disability register validation (p12) | Dementia register · Dementia: QOF prevalence · Learning disability register | 66.7% diagnosis ambition · 95% care plan 2027 · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
